Cell membrane material targeting multiple myeloma cells and uses thereof

By expressing anti-GPRC5D antibodies on the surface of multiple myeloma cell membranes, targeted cell membrane materials were prepared and nanomedicines were encapsulated, solving the problems of insufficient tumor targeting and systemic toxicity in the treatment of multiple myeloma, and achieving precise drug delivery and efficient anti-tumor effects.

CN122681818APending Publication Date: 2026-09-04WEST CHINA HOSPITAL SICHUAN UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202610819310.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-08
Publication Date
2026-09-04

AI Technical Summary

Technical Problem

Multiple myeloma treatments lack sufficient tumor targeting and are prone to causing systemic toxicity. Furthermore, existing research, such as CAR-T cell therapy, suffers from high costs, long preparation cycles, and the potential risk of cytokine storms.

Method used

By expressing anti-GPRC5D antibodies on the surface of multiple myeloma cell membranes using genetic engineering techniques, targeted cell membrane materials were prepared, and active drug molecules were encapsulated in nanoparticles. Precise delivery was achieved by utilizing the specific recognition of the antibody and the GPRC5D receptor.

Benefits of technology

It improves the drug's ability to accumulate in the bone marrow microenvironment, reduces toxic side effects on normal tissues, enhances drug utilization efficiency and anti-tumor activity, and provides higher treatment safety and precision.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and particularly relates to a cell membrane material for targeting multiple myeloma cells and a preparation method and application thereof. The technical problem to be solved by the application is that myeloma cell treatment drugs lack sufficient bone marrow barrier delivery and tumor targeting, and are prone to cause systemic toxic side effects. The technical solution for solving the technical problem of the application is to provide a cell membrane material for targeting multiple myeloma cells. The membrane material is the cell membrane of cells expressing antibodies against GPRC5D on the surface. The cell membrane material of the application inherits the bone marrow homing effect of the membrane source cells to enhance the delivery of drugs across the bone marrow barrier, and has active targeting and binding capacity for the GPRC5D ligand on the surface of multiple myeloma cells, so that the drugs can be efficiently delivered to the tumor site in the bone marrow cavity and efficiently taken into multiple myeloma cells, and then the precise enrichment and release of the drugs at the bone marrow lesion can be realized, so that the treatment effect is improved, the systemic toxicity is reduced, and an effective drug carrier scheme is provided for the treatment of multiple myeloma.
Need to check novelty before this filing date? Find Prior Art